Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies
() -- Mira Pharmaceuticals (MIRA) said Monday that preclinical studies evaluating the oral formulation of SKNY-1 for obesity and addiction-related disorders showed "favorable" bioavailability along with reproducible systemic exposure and robust brain penetration. The studies further showed substantial liver exposure fo